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This project describes the development of a new antitumor therapeutic platform that combines
the benefits of small-molecule drug conjugates (SMDCs) and antibody drug conjugates
(ADCs). Valine-citrulline (VCit) dipeptide linkers are popular cathepsin B cleavable ADC
linkers. Due to its instability in mouse serum, translating efficacy data from mouse to human
is more difficult. It has been reported that replacing the VCit linker with glutamic acid-valinecitrulline (EVCit) improves ADC stability in mouse serum. The effect of the EVCit linker on
the stability of SMDCs has not been reported so far. In a xenograft mouse model of prostate
cancer, we found that incorporating the EVCit linker in PSMA-targeting SMDCs equipped
with the transthyretin ligand AG10 resulted in conjugates with lower toxicity, extended halflife, and superior therapeutic efficacy compared to the standard metastatic castration-resistant
prostate cancer (mCRPC) treatment option, docetaxel. This should improve the predictability
of SMDC preclinical toxicity and efficacy data from mice.
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CHAPTER 1: INTRODUCTION

1.1. Cancer
Cancer still remains one of the major public health threats worldwide and is the second
leading cause of death in the United States. According to cancer statistics, just under 2 million
estimated new cases and 609,360 estimated deaths are projected in 20221. It is the second most
common cause of death worldwide with approximately 8.2 million each year. Normally,
human cells grow in an orderly manner and when cells grow old, they are either damaged or
died while newer cells take their place. Sometimes due to genetic changes multiple factors
break down this orderly process causing uncontrolled growth of damaged or abnormal body
cells. These cells have the ability to ignore programmed cell death/apoptosis, trick immune
cells of its cause and grow beyond their starting location, and invade neighboring tissues or
other parts of the body 2. These cancer cells form their own microenvironment to ensure the
intake of different kinds of nutrients or other materials necessary for faster growth and
proliferation than normal cells 3. Cancers are generally named after the location (organs or
tissues) of the tumor where it first formed. Another way of classifying tumors is solid and
liquid tumors. The solid tumor generally forms single mass lacking cysts or liquid areas while
liquid tumors found in bodily fluids, move throughout the body by the bloodstream and are
detected through blood testing. Sarcomas (cancers in bone and soft tissues such as muscle, fat,
blood vessels, lymph vessels, and fibrous tissue such as tendons and ligaments) and carcinomas
(cancers in epithelial tissues such as skin, gland ureter, and kidney) are generally referred to as
solid tumors. Liquid tumors include leukemias (cancers in bone marrow such as white blood
cells and red blood cells) and lymphomas (cancers in B cell and T cell build up in lymph nodes
and lymph vessels).
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1.2. Chemotherapy
The discovery of X-rays by Wilhelm Konrad Roentgen, the learning to utilize animaltumor models in cancer research, and the development of surgical procedures by Halsted led
to the development of cancer treatment in the last century 4. Failure of surgery and radiation
therapy to eradicate metastatic cancer in the early years placed more emphasis on the
development of drugs, biological molecules, and immune-mediated therapies and
chemotherapeutics
methotrexate.

4

.

The early-stage chemotherapeutics are cyclophosphamides and

Later, hormone therapy was invented in the mid-20th century

5

.

Chemotherapeutics interfere with tumors at the cellular level by interrupting processes or
inhibiting substances required for cellular replication and survival. Combination of more than
one chemotherapy gained the confidence to combat cancers that become resistant to solitary
drugs.

Chemotherapeutics are classified based on their mechanism of action including

alkylating agents such as nitrogen mustard, nitrosourea, platinum analogs, and triazenes,
antimetabolites such as cytidine analogs, folate antagonists, purine and pyrimidine analogs,
antimicrotubular agents such topoisomerase I & II inhibitor, taxanes, and vinca alkaloids

4,5

.

Although these agents have IC50 values ranging from picomolar to micromolar concentration
against different cancer cells, their unique disability is to distinguish between normal cells and
target cancer cells causing toxic side effects including myelosuppression (bone marrow
functionality suppression), thrombocytopenia (deficiency of platelets), and peripheral
neuropathy (nerve damage) 6. Now, targeted therapy presents a potential solution for lowering
the toxic effects of chemotherapeutics by preventing passive diffusion and concentrating on
tumor biomarkers overexpressing cells.
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1.3. Targeted Therapy
Targeted anticancer therapy is an exponentially growing class of chemotherapeutic
agents with advantages over conventional anticancer drugs. It has become an effective tool of
precision medicine for improving cancer treatment due to selectivity improvement which is
always the goal in modern oncology because of decreased side effects compared to
chemotherapy 7. Targeted therapy can maximize the therapeutic potential while minimizing
toxic side effects. These advantages are a result of selective targeting of the cytotoxic agent
towards cancer cells over normal cells. Targeted anticancer therapeutics consist of a chemical
linker acting as a spacer bridge between the cytotoxic payload and the targeting moiety.
Different types of targeting moieties have been utilized and reported for targeting specific
cancers such as antibodies, proteins, peptides, peptidomimetics, and small molecules 7. The
selectivity is typically achieved by utilizing a targeting moiety that interacts specifically with
a marker protein that is present on the surface of cancer cells. Target biomarker expression in
tumor cells is essential for this approach to be successful.

Two common criteria are

overexpression compared to normal cells and expression level has to be sufficient to cargo
desired concentration of drug for receptor-mediated endocytosis. Three times overexpression
of biomarker/receptor is considered sufficient for targeted therapy to work, however, greater
upregulation is considered better

7,8

. Receptors should be expressed on the surface (apical

surface) of the cell, not on the cytoplasm or the nucleus. Receptor recycling is a factor for
effective targeting which generally happen to a greater extent in cancer cells than normal 7.
Higher recycling of receptors allows for increased delivery of targeted drugs. The ideal
receptor for targeted therapy comeback on the surface frequently, avoiding degradation inside
cells, or resynthesized rapidly following degradation. The binding affinity of the ligand
towards the receptor is crucial for targeted therapy. The general rule is that the higher the
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binding affinity of the ligand for receptor the lower the concentration of drug needed to saturate
the receptor. In addition, selectivity is highly desirable for ligands as they should not select the
receptors of the same class that does not present in tumor cells. Lower molecular weight ligand
drug conjugates have been found to be better in terms of tumor accumulation 7–9.
1.3.1. Antibody-Drug Conjugates (ADCs)
Over the past decades, antibody-drug conjugates (ADCs) have gained enormous
popularity in oncology therapeutics 7. They are a great combination of chemotherapy and
immunotherapy 10. The first concept of ADC was provided by German physician and scientist
Paul Ehrlich who described the antibody as a “magic bullet” that has the ability to identify its
target by itself sparing nontarget. Initially, in the 1980s the effort fails due to immunogenicity
caused by antibodies generated from murine 11,12. Recent advances in humanized antibody and
phage-display technologies lead to the widespread use of monoclonal antibodies and antibody
fragments in oncology therapeutics

13

. Currently, fourteen ADC has been approved by the

FDA for different cancer and about 100 of them are in different stages of clinical trial 12. Due
to their endogenous property and higher molecular weight ADCs have the advantage of high
specificity, high binding affinity for target tissues, and long circulation half-life (t1/2) over
conventional low molecular weight chemotherapeutic agents 14. ADCs are proteins in nature
and have large molecular weight (MW ~150 kilodaltons; kDa) manifested into limited
penetration of tumor tissue, particularly when the binding affinity of antigens to target receptors
is high. In addition, systemic and endocytic antibody clearance are culprits to decreased
antibody penetration and failure of cytotoxic agent to saturate tumors 15. In addition, the lack
of oral bioavailability, elaborate conjugation chemistry, and high production cost of ADC is
considered as drawbacks in industrial settings. As ADCs stayed in circulation for longer
periods of time, premature release of the cytotoxic payload due to linker system instability may
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result in off target toxicity 7. While the large size of ADCs limits the nonselective distribution
of the cytotoxic agent into healthy cells and tissues, it also reduces their rate of diffusion and
extent of penetration into solid tumor tissues. Therefore, the majority of approved ADCs and
the ones in clinical trials are used in hematologic cancers. The limited number of ADCs used
in the treatment of solid tumors led many to explore alternative, smaller-format drug conjugates
with better tumor penetrating properties 7,16,17 .
1.3.2. Small Molecule Drug Conjugate (SMDCs)
Small molecule-drug conjugates (SMDCs) have great promise as a new class of
targeted cancer therapeutics. Compared to ADCs, small molecule-drug conjugates (SMDCs)
are a relatively new, and less well-established class of targeted delivery. However, SMDCs
pose several advantages over ADC such as non-immunogenicity, amenable to classic largescale organic synthesis, and smaller size which are found to be a higher potential for solid
tumor penetration. SMDC are composed of small molecules which makes it lower cost in
industry level manufacturing. Therefore, SMDCs might be a great replacement for ADCs with
similar efficacy.

SMDCs are typically BiFunctional Molecules (BFMs) that consist of

targeting ligands and cytotoxic payloads chemically conjugated by a suitable linker system 7,18
. The main difference between ADCs and SMDCs is their targeting ligands. SMDC has a
similar building block as ADC except that the targeting moiety in ADCs (biological antibody
size ~150 kDa) is replaced by smaller targeting ligands in SMDCs, which are generally
peptides or peptidomimetics (size < 5 kDa) in nature 19. The targeting ligand is selected based
on binding affinity, target selectivity, and the size of the conjugates. Increased binding affinity
would allow for reducing the dose required for efficacy. Binding selectivity act on lowering
the off-target toxicity by avoiding healthy cells. The size of conjugates also plays important
roles in drug delivery via different mechanisms including permeability, retention, and excretion
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through the kidney for SMDC. The most commonly investigated and advanced targets for
SMDCs are folate receptors, prostate-specific membrane antigen (PSMA), glucose transporter
1 (GLUT1), aminopeptidase N (APN), and low-density lipoprotein receptor-related protein 1
(LRP1), avb3, bomblesin receptor, and somatostatin receptor (SSTR)

20

. One of the major

issues with SMDCs is their short in vivo half-life because of their smaller size (e.g., the halflife for vintafolide and etarfolatide is ∼25 min) 7,20. SMDCs that employ low-molecular weight
hydrophilic small molecules or peptides as targeting moieties (e.g., vintafolide, etarfolatide,
and
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Lu-PSMA-617 were/are in most advanced stage)

21–23

. The small size of SMDCs

(typically ~1 to 5 kDa) allows for better tumor penetration, especially in the case of solid
tumors.

In addition, the hydrophilicity of the targeting ligand increases the overall

hydrophilicity of the hydrophobic cytotoxic payload in the LTD which limits its nonselective
passive tissue distribution and toxicity to healthy cells. On the other hand, hydrophilic small
molecules are readily cleared through the kidneys within 30 min of injection (size cutoff for
molecules to be cleared through glomerular filtration is ~30 kDa) 24. The short in vivo half-life
of SMDCs (e.g., t1/2 for vintafolide and etarfolatide is ~25 min) reduces their exposure to
receptor-expressing target tissues which prevents optimal tumor uptake 7. Therefore, requires
frequent administration which oftentimes results in dose-limiting toxicity

7,20

. The linker is

designed to optimize the function of drug release, pharmacokinetics, and pharmacodynamic
properties. The linker should be stable in circulation and cleaved to release cytotoxic payload
effectively only after the SMDC reaches its target. Although hydrophobicity of the therapeutic
payload maximizes membrane permeability and receptor affinity, a balance of hydrophilicity
in the linker system is desirable to prevent passive diffusion towards healthy cells and make it
difficult for SMDC to penetrate cell membranes without receptor-based endocytosis. The
linker system in ADCs can be enzymatically cleavable or non-cleavable. However, for SMDC
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the non-cleavable linker can add complexity and uncertainty to the mechanism. For ADC, the
non-cleavable linker sometimes added extra protection against off-target cleavage and release
cytotoxic metabolites by the proteolytic degradation of the antibody part 25–27. In most cases,
the targeting ligand portion of a SMDC is stable by itself and has less chance of releasing
cytotoxic metabolites inside the tumor microenvironment. Therefore, the majority of reported
SMDCs utilizes only cleavable linkers.
1.4. Approaches for Enhancing the t1/2 of Therapeutic Agents
To improve the t1/2 of small molecules and biotherapeutic drugs, various approaches
have been used. Covalent protein conjugation to polyethylene glycol (PEG) polymers of up to
40 kDa size was found to extend protein in vivo half-life

28–30

. PEG polymers can be

synthesized as linear or branched chains with functional groups at the termini to allow for a
wide range of conjugation procedures which is commonly conjugated to macromolecules such
as proteins via stable or hydrolyzable linkages

28–30

.

PEG conjugation increases the

hydrodynamic size of proteins while decreasing glomerular filtration by the kidneys. The
hydrophilic mobile PEG moiety protects proteins from proteolysis through a dynamic process
that creates steric obstruction over the domain of the protein that acts as the proteolytic
substrate 30. This, however, comes at the expense of decreased binding affinity for the target
30

. Furthermore, the chemical conjugation process and PEG heterogeneity typically result in

complex product mixtures. Furthermore, high doses of PEGylated molecules have been linked
to renal tubular vacuolation and toxicity. This is due to PEG's non-biodegradable nature, which
is primarily excreted unchanged by the kidneys 31. In humans, specific antibodies against PEG
have been reported to be induced after the administration of PEG-conjugated drugs, and preexisting anti-PEG antibodies have been identified in more than 25% of the healthy population
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who have already exposed to PEG previously.

This resulted in increased risk of

immunogenicity from PEG 32.
Protein conjugation to human serum albumin (HSA) has also improved the half-life of
biotherapeutic agents such as insulin and GLP-1. HSA has a particularly long circulatory t1/2
of 19 days. Albumin’s MW is 66.5 kDa (which is greater than the renal filtration cut-off of 30
kDa). In addition, albumin can specifically interact and recycled by neonatal Fc receptors
(FcRn). Albumin binds FcRn with high affinity at low pH in the acidic endosome. This results
in diverting albumin from the lysosomal degradation pathway and allow albumin to be recycled
back to circulation 33.
Therapeutic drugs attached to HSA binding molecules (HSA tags) increased t1/2
proportionally to their HSA binding affinity 34. These HSA tags failed to retain therapeutic
effectiveness in vivo due to the strong binding affinity of these ligands to HSA and its high
molar abundance (600 μM, 60% of the plasma protein pool)30. In chronic situations like Type
II diabetes, over-extended 19 days t1/2 in albumin GLP-1 conjugates is desirable however,
prolonged exposure to therapeutic agents can cause serious side effects, especially in diagnostic
applications [e.g. ProstaScint® (Cytogen Corporation, Princeton, NJ),

111

indium capromab

pendetide, radiolabelled anti-PSMA antibody for prostate cancer and peptide hormones [e.g.
Carbetocin, an obstetric drug used to control postpartum bleeding]

35,36

.

SMDCs with

hydrophilic DOTA chelators as payloads and hydrophobic small-molecule albumin binders as
conjugates have reported longer circulation times and higher tumor uptake 37. SMDCs with
cytotoxic medicinal payloads, which are usually ultra-potent hydrophobic small molecules,
have not been successfully albumin-bound (e.g. auristatins and maytansinoids). Conjugation
to lipophilic albumin binders increases conjugates' hydrophobicity, which may lead to
aggregation, micelle formation, or nonspecific diffusion and adsorption to off-target cells 7,20.
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Thus, enhancing SMDC’s in vivo half-life while keeping their hydrophilicity and reduced size
could improve selectivity and tumor penetration, resulting in effective cancer treatment.

Figure 1. Crystal structure of homo-tetrameric transthyretin (TTR) bound to AG10.
Monomers are colored individually (PDB ID: 4HIQ) 38. Two AG10 molecules are bound in
the two thyroxine (T4) binding site in TTR.
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1.5. Previous Approaches for Enhancing safety and efficacy of SMDC
In the past, Alhamadsheh’s lab has repurposed the potent TTR stabilizer, AG10 (Figure
1), for half-life extension of peptides 38. This was achieved by linking the AG10 (currently in
Phase III clinical trial for cardiac amyloidosis) conjugate to peptides to increase their stability.
As a proof of concept, AG10 was conjugated to hydrophilic peptides (GnRH; Log P -3.6) by a
suitable linker system and found a significant increase in half-life

38

.

The poor

pharmacokinetics of SMDCs can be overcome by outfitting the typical bifunctional SMDCs
with an additional arm containing the hydrophilic transthyretin (TTR) binding ligand AG10,
thereby forming TriFunctional Molecules (TFM) which overcome the poor pharmacokinetics
of SMDCs. The TFM approach was successful in improving the targeting efficiency of
SMDCs containing hydrophilic Cy7 or hydrophobic monomethyl auristatin E (MMAE), while
simultaneously maintaining their small size. This resulted in the enhancement of targeting
efficacy of the SMDCs against prostate cancer cells 7.
In comparison to ADCs (~ 150 kDa), the size of TTR molecule is only 55 kDa, making
our method potentially advantageous in multiple ways. There is no information that has been
presented regarding the diffusion rate of TTR into the microenvironment of the tumor. While
TTR is about the same size as human serum albumin (66 kDa), comparing the rate of diffusion
with albumin in solid tumor is more relevant. The concentration gradient of a protein acts as
the primary mechanism for diffusion into the tumor. Compared to the interstitial fluid, there is
a relatively high concentration of albumin present in the blood which facilitates its diffusional
movement into the tumor microenvironment 33. Albumin and TTR both have concentrations
that are stable in the blood which keeps the constant concentration gradient between blood and
the tumor microenvironment. Therefore, smaller proteins, such as albumin and TTR should
have a higher diffusion rate than larger ADCs, resulting in deeper permeation into the tumor
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tissue. On the other hand, systemic clearance lowers the concentration of protein therapies in
the blood, which hampers the saturation of drugs to the tumors 7. As a result, the TTR method
has the ability to circumvent the inadequate pharmacokinetic features of SMDCs and smaller
proteins. The act of binding to TTR in the blood will result in an increase in the effective
molecular weight of these smaller molecules, resulting in the extension of their half-life while
still allowing for improved penetration into the tumor tissue.
1.6.Valine-Citrulline (VCit) Linker Instability in Mouse Serum
The linkers in ADCs and SMDCs should be carefully designed to optimize functions
such as payload release, pharmacokinetics, toxicity, and efficacy

39,40

. These linkers are

designed to be stable in serum and only release potent cytotoxic agents when the therapeutic
agents are selectively taken up by cancer cells within the tumor microenvironment. Valine–
citrulline (VCit) linker is the most popular and well-established lysosomal cathepsin cleavable
linker. At least 3 ADCs (ADCETRIS, POLIVY, and PADCEV) so far utilized this linker for
conjugating payloads and target antibodies. It was found that this linker is stable in human
serum and hydrolyzed by human lysosomal cathepsin B. Surprisingly, this linker is cleaved in
mouse serum which poses a disadvantage in terms of unintended toxicity (Figure 2). To
investigate, Dorywalska et al 2016, discovered that carboxylesterase 1c (Ces1c), an
extracellular enzyme in the serine hydrolase class, is responsible for extracellular cleavage of
the VCit linker. The binding pocket of the human form of this enzyme is positioned deep
within a narrow-elongated pocket which makes it inaccessible for substrate binding and
cleavage. The binding pocket for human cathepsin B is wide and shallow which is easily
accessible by the substrate. That gives the hint that Mouse Ces 1c might have a wide and
shallow substrate binding pocket which makes them accessible to VCit linker resulting its
hydrolysis in mouse serum 39. One approach to ameliorate the instability in mouse plasma is
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selecting suitable antibody binding sites that can sterically protect the labile site from the Ces
1c enzyme. Another approach to circumvent this problem is to use Ces 1c knockout mice.
However, SMDCs most often don’t have the option of multiple binding sites and knockout
mice can add complexity for the smooth transition of efficacy and safety data from mouse to
human. Our first-generation TFMs incorporate the cleavable well established (VCit) dipeptide
linker, widely used in ADCs 41. In agreement with the discussion above, VCit linker containing
SMDCs are relatively stable in human serum and cleaved by cathepsin B upon internalization
by target cancer cells, resulting in free payload release39,40. However, the instability of the VCit
linker in mouse serum results in premature release of the cytotoxic payload in the systemic
circulation, causing unwanted toxicity in the mouse model and preventing from evaluation of
higher doses for efficacy and safety making the VCit-TFM molecule with extremely narrow
therapeutic window. Despite demonstrating stability in human serum, the stability data in mice
are crucial since almost all preclinical studies for anticancer drug development are performed
in mouse models

40,42

.

Therefore, establishing good serum stability for these targeted

anticancer agents in mouse serum is essential for the effective translation of preclinical results
from mouse models to human clinical trials.
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Figure 2. Structures and plasma stability of cathepsin-responsive VCit cleavable peptides. VCit
linkers in ADCs are unstable in mouse plasma for ADC due to susceptibility to the mouse
extracellular carboxylesterase Ces1c.
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1.7. EVCit Linker for Stability in Mouse Serum
After discovering that the enzyme (Ces 1c) is responsible for the extracellular
hydrolysis of VCit linker, the exploration began to investigate, how to sterically protect the
linker from mouse Ces 1c while retaining the substrate binding and lysis activity of cathepsin
B. From the structure and its interaction with the human cathepsin B enzyme it was speculated
that the linker position immediately preceding the valine residue, that is, the P3 position
upstream of the enzymatic cleavage site is positioned at the edge or outside of the cathepsin B
binding pocket. That gave the idea that modification at P3 position is unlikely to hamper
cathepsin cleavage. After that, an investigation has been done to incorporate hydrophobic
residues with different steric bulk at the P3 position. Subsequently, the hydrophilic residue at
P3 position has been investigated and drastic improvement was observed when acidic side
chains such as aspartic acid (D), glutamic acid (E) is introduced. To understand the mechanism,
a basic side chain containing amino acids such as lysine (K) was incorporated at the P3 position
and found that the basic side chain facilitates the cleavage even at a faster rate than VCit linker
in mouse serum. These results indicated that acidic side chains at P3 position repels Ces 1c
access while the basic side chain facilitates access. All the conjugates show comparable
hydrolysis power by lysosomal proteolytic enzyme. Replacing the VCit linker with glutamic
acid–valine–citrulline (EVCit) has been found to be most effective in enhancing the stability
of ADCs in mouse serum (Figure 3)40. The introduction of the hydrophilic glutamic acid in the
linker increased ADCs stability in mouse serum (by enhancing resistance to mouse Ces1cmediated degradation) without hampering the reactivity of ADCs to intracellular cathepsin Bmediated cleavage

40

. However, to our knowledge, the effect of the EVCit linker on the

stability of SMDCs has not been reported yet. In this study, we investigated the stabilizing
effect of the EVCit linker, in comparison to VCit linker, on SMDCs’ toxicity and efficacy
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profiles. Here, we showed that an EVCit-TFM (TFM with the EVCit linker) conjugate is
responsive to enzymatic drug release by cathepsin B but undergoes lower premature cleavage
of the linker in mouse serum compared to a VCit-TFM conjugate (TFM with a less stable VCitlinker). We demonstrated that EVCit-TFM exhibited lower toxicity in mice than VCit-TFM.
Due to the extended circulation half-life, through binding to TTR, EVCit-TFM also showed
greater treatment efficacy in a xenograft mouse model of prostate cancer than docetaxel and
EVCit-based bifunctional SMDCs variant (i.e., EVCit-BFM). Our data showed that the EVCit
linker enhanced the stability of SMDCs in mouse serum, but to a lesser degree than enhancing
the serum stability of ADCs (likely due to much larger sizes of ADCs) 43. The incorporation
of the EVCit tripeptide linker in the TFM approach could add flexibility to the SMDCs design.
This should also make it easier to correlate the data between mice and human, which would
increase the success rate for translating preclinical studies for this class of targeted molecules.
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Figure 3. Structures and plasma stability of cathepsin-responsive EVCit cleavable peptides.
EVCit-based tripeptide sequences with an acidic side chain such as EVCit are responsive to
cathepsin-mediated cleavage but are highly stable in mouse plasma when incorporated into
ADCs.
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CHAPTER 2: TRANSTHYRETIN: A CARRIER PROTEIN

2.1. Transthyretin
Transthyretin (TTR) is a 55 kDa homo-tetrameric protein found in plasma and
cerebrospinal fluid (CSF).

It is primarily produced in the liver and secreted into the

bloodstream, where it serves as a backup carrier of thyroxine (T4) and the primary carrier of
holo retinol-binding protein (RBP) which carries retinol (Figure 4) 44–46.

Figure 4. Schematic model of TTR bound to T4 and holo-Retinol–binding protein (holoRBP).
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2.2. TTR Expression
The liver is largely responsible for producing plasma TTR, whereas the choroid plexus
is responsible for producing TTR in the brain. TTR is also produced in smaller quantities in a
number of other tissues, including the meninges, islets of Langerhans of the pancreas, the gut,
and the retinal pigment epithelium of the eye

47

. TTR is a substance that is generated and

secreted by hepatocytes in the liver. In healthy adults, typical TTR concentrations range from
20 to 40 mg/dL (3.5-7 µM) 48. Therefore, there is a considerable drop in blood TTR levels
when the liver is taking part in the acute phase response to injury, starvation, or chronic
inflammation. Due to its shorter half-life of about 2 days compared to 19 days for albumin,
TTR could be used as a marker for nutritional and inflammatory status in the clinic, especially
in critically ill patients where TTR should be more suitable to determine the progression of the
patient's health.
2.3. TTR Structure
Human TTR is a homotetramer composed of four identical 127 amino acid residue
subunits (~14 kDa per subunit) that form an extensive β-sheet structure 49. The four identical
subunits (or monomers) of TTR assemble to form an internal channel at the weaker dimer–
dimer interface where two thyroid hormones (T4) molecules could bind on the resulting
tetramer 47,50. Due to the presence of two other T4 transport proteins in the blood, the TTR T4
binding sites remain largely unoccupied in humans (<1 % T4 bound) and among those
occupied, only one site is filled as there is negative cooperativity in the binding of the second
T451,52. The main function of TTR in the blood is the transport of holo-retinol binding protein
(holo-RBP). The binding site of holo-RBP on TTR is orthogonal to that of T4 (Figure 4). In
addition to T4 and holo-RBP, several other pharmacologic agents and natural products, such
as plant flavonoids, nonsteroidal analgesic drugs, and inotropic bipyridines, are strong
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competitors for T4 binding to TTR and have binding affinities greater than T4 47. Human wildtype TTR (WT-TTR) structure was one of the first to be determined using X-ray
crystallography 45. As of October 2015, the Protein Data Bank (PDB, www.rcsb.org) contained
approximately 241 reported TTR crystal structures and variants representing five protein
species (human, rat, mouse, chicken, and fish). According to the findings so far, the amino
acid sequence of human WT- TTR is about 85% identical to that of other species 53. TTR
subunits (monomers) are made up of eight -strands labeled A to H and one short helix. These
eight strands combine to form two sheets, D-A-G-H and C-B-E-F, which together form an
immunoglobulin-like barrel structure. The two monomers dimerize primarily via H-strands
forming antiparallel main-chain interactions and F-strands forming interactions between side
chains and interconnecting water molecules.

Following that, these dimers interact via

hydrophobic interactions between the AB and GH loops, resulting in the formation of a
tetramer with a hydrophobic channel between the dimers where T4 binds 54. The T4 binding
site is divided into three halogen-binding pockets (HBP), which are designated as HBP1,
HBP2, and HBP3. HBP1 is the channel's outermost component, consisting of the side chains
Met13, Lys15, and Thr106. The side chains of Leu17, Ala109, and Leu110, as well as the
hydrophilic main chain carbonyl groups of Ala108 and Ala109, make up the middle portion of
the channel. HBP3 is the channel's final and innermost segment, consisting of the side chains
Ala108, Ala109, Leu110, Ser117, and Thr119. The hydrophilic portion of HBP3 is formed by
the Ser117 and Thr119 side chains, as well as the carbonyl and amino groups of Ala108,
Ala109, Leu110, and Thr118 in the main chain.
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2.4. Physiological Function of TTR
TTR's most studied and recognized role is the transport of retinol (vitamin A), but new
research suggests that TTR may also play an important physiological role in proteolysis and
the transport of other miscellaneous ligands 55.
2.4.1. TTR as a Transporter
TTR is not the main transporter of T4 (less than 1% is bound), and the T4 binding sites
in humans are mostly empty because thyroxine-binding globulin (TBG) and albumin present
in the blood carry T4 56,57. However, TTR is a major T4 transporter in the CSF of both humans
and rats. In rats, TTR is the primary transporter of T4, which is different from humans.
Because of the negative cooperativity of the two T4 sites in TTR, each TTR tetramer can only
be bound to one T4 molecule at a time 58. In the blood, retinol is attached to a protein called
retinol-binding protein (holo-RBP), which is present in a complex with TTR. Binding to TTR
helps RBP get out of its place of production in the endoplasmic reticulum and stops RBP from
being filtered by the kidneys 59,60. For a stable complex to form between RBP and TTR, retinol
needs to be bound to RBP 61. The structural investigation reported that the RBP binding site
on TTR is not in the same place as the T4-binding pockets on TTR (Figure 2)46. Due to the
low concentration of RBP in plasma, it binds to TTR in a 1:1 molar ratio. On the other hand,
in vitro studies have shown that one TTR tetramer can bind up to two RBP molecules when
there are more RBP molecules present 44.
2.4.2. TTR as a Protease
TTR has been found to exhibit proteolytic activity in addition to being a transporter of
T4 and RBP. TTR is known to associate in small amounts with both low-density (LDL) and
high-density lipoproteins (HDL), with apoA-I, a significant HDL apolipoprotein, accounting
for roughly 1-2% of the total plasma TTR in circulation

55

. The C-terminus of apoA-I was
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cleaved as a result of TTR, and apoA-I's physiological conditions induced incubation. This
cleavage by TTR causes apoA-I to become more amyloidogenic and less effective at promoting
cholesterol efflux, which leads to the onset of atherosclerosis. The preventive effects of TTR
against amyloid beta (Aβ) deposition in Alzheimer's disease (AD) have recently been
demonstrated 44. According to studies, TTR can bind to and cleave soluble (Aβ) which stops
the in vitro formation of Aβ amyloid fibrils44. TTR splits Aβ in several places, resulting in
shorter Aβ peptides with lesser amyloidogenic potential. Additionally, TTR was able to break
down aggregated forms of Aβ, which may help to maintain normal Aβ levels in the brain. TTR
can cleave neuropeptide Y (NPY), among other things, and may potentially help maintain
neuropeptide homeostasis45.
2.4.3. Miscellaneous Roles of TTR
Several other TTR ligands identified including norepinephrine oxidation products,
yellow compounds (carotenoids) such as lutein and pterin, proteoglycans such as perlecan,
Lysosome-Associated Membrane Proteins (LAMP-1), Metallothioneins (MT2), flavonoid and
xanthone derivatives) 55.
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CHAPTER 3: EVCit LINKER MEDIATED AND TTR-BASED TARGETED DRUG
DELIVERY SYSTEM

3.1. General Concept of a Stable Trifunctional Molecule
We have reported that the poor pharmacokinetics of BFMs can be overcome, while
maintaining their hydrophilicity and small size, by outfitting them with an additional arm
containing the hydrophilic TTR binding ligand (i.e., forming TriFunctional Molecules, TFMs)
62

. To establish the proof of concept we designed these TFMs to deliver a hydrophilic small

molecule imaging agent, Sulfo-Cyanine 7 (Cy7; a water soluble indocyanine 7 dye for nearinfrared (NIR) in vivo imaging), or a lipophilic cytotoxic agent (monomethyl auristatin E,
MMAE) to PCa cells overexpressing the prostate-specific membrane antigen (PSMA) (Figure
5). PSMA is a transmembrane protein that is largely absent from healthy tissues but highly
expressed on the surface of PCa cells and on new blood vessels that supply nutrients to many
other types of cancers

63,64

. PSMA is also highly overexpressed in metastatic castration-

resistant prostate cancer (mCRPC) and therefore targeting PSMA is considered a promising
target both for imaging and chemotherapeutic agents 65–67.

38

Figure 5. Schematic illustration of the concept for the TTR-based targeted drug delivery
approach. TFMs are comprised TTR binding ligand (blue), PSMA ligand (black), and
Payload (Cy7 or MMAE in red). The hydrophilic TTR ligand allow TFMs to bind reversibly
to circulating TTR, thereby reducing its renal clearance and enhancing its in vivo t1/2. The
overall hydrophilic nature of TFMs, in addition to binding to TTR, would also reduce the
non-selective tissue distribution of TFMs to normal cells. The PSMA targeting module
allows the TFMs to selectively deliver the therapeutic payload of these TFMs to its
intracellular targets in PSMA+ prostate cancer (PCa) cells. The binding affinity of TFMs to
PSMA is higher than its binding to TTR, which allows the TFMs to preferably interact with
PSMA over TTR. The linker system we used is too short to bring the two proteins in close
proximity to each other, which prevents the formation of the ternary complex 62.
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3.2. Design and Synthesis of EVCit-TFM and EVCit-BFM with Stable EVCit
Tripeptide Linker.
We have previously reported that incorporating the VCit linker in TFMs targeting
prostate cancer cells (e.g., VCit-TFM; compound 1; Figure 6) efficiently released the payload
after internalization in cancer cells and suppressed tumor growth in the mouse xenograft
models of prostate cancer 62. While VCit-TFM was stable in human serum, the instability in
mouse serum hampered the evaluation of higher doses of VCit-TFM for an extended period.
We hypothesized that incorporating the EVCit tripeptide linker in our TFM will allow us to
enhance its safety profile. To test our hypothesis, we designed a TFM similar to our reported
VCit-TFM, with the exception of adding glutamic acid to the cathepsin B cleavable linker,
forming EVCit-TFM (compound 2; Figure 6). Both TFMs utilized low molecular weight
glutamate-urea-lysine ligand as targeting ligand, which is highly selective for prostate-specific
membrane antigen (PSMA). The antimitotic agent, MMAE, was used as the cytotoxic payload.
To increase the half-life of the newly designed EVCit-TFM, our approach involved endowing
the TFMs with AG10, a small molecule that binds reversibly to the serum protein transthyretin
(TTR)

38,62

. Our group has discovered AG10 which is currently in Phase 3 clinical trials for

ATTR cardiomyopathy

68,69

. TTR is a 55 kDa serum protein that is made by the liver and

secreted into blood (concentration ~5 μM) with a circulation half-life of ~2 days 70. TTR in
humans is the primary transporter of holo-retinol binding protein (holo-RBP) in blood 70. TTR
acts as a back-up carrier of thyroxine (<1% thyroxine bound), utilizing orthogonal sites to those
of holo-RBP 71. We have shown earlier that AG10 and TFMs bind to the two thyroxine sites
in TTR, and this binding does not interfere with the binding of holo-RBP to TTR

38,62

. As a

control for a typical bifunctional SMDC, we also synthesized EVCit-BFM (compound 3;
Figure 6), which consists of the targeting ligand and payload used in EVCit-TFM, except
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without the TTR ligand AG10. The synthesis of VCit-TFM was reported earlier

62

. The

synthesis of EVCit-TFM and EVCit-BFM is shown in Schemes 1. All compounds tested had
>95% purity (C4 and C18 HPLC purity analysis of EVCit-TFM and EVCit-BFM can be found
in; Figures 18 and 19).

Figure 6. Chemical structures of VCit-TFM, EVCit-TFM, and EVCit-BFM. The TTR ligand
AG10 (blue), PSMA ligand (black), Payload MMAE (red), and linker system (brown) except
for Glutamic acid (green). VCit-TFM has the cathepsin B cleavable VCit dipeptide linker,
while EVCit-TFM and EVCit-BFM have the more stable cathepsin B cleavable EVCit
tripeptide linker.
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Scheme 1. Synthesis of EVCit-TFM and EVCit-BFM

a

Reagents and conditions: (a) Piperidine, DMF, rt, 30 min; (b) 6-Maleimidohexanoic acid Nhydroxysuccinimide ester, DMF, rt, 24 h; (c) HFIP, DCM (80% yield over 3 steps); (d) i. NHS,
DCC, THF, rt, 24 h; ii. DIPEA, DMF, compound 5 rt, 12 h (43% yield); (e) i. Bis (4nitrophenyl) carbonate, DIPEA, DMF, rt, 2 h; ii. MMAE, HOBT, Pyridine, DMF, rt, 24 h (40%
yield); (f) i. 20%TFA in DCM, 0 ºC, 2 h, then NH4OH, ii. Compound 8, TEA, DMF, rt, 5 h
(33% yield); (g) i. 20%TFA in DCM, 0 ºC, 2 h, then NH4OH, ii. Compound 9, TEA, DMF, rt,
5 h (30% yield).
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CHAPTER 4: RESULTS

4.1. EVCit-TFM and EVCit-BFM are More Stable in Mouse Serum Compared to VCitTFM.
In this study, we compared the stability of EVCit-TFM and EVCit-BFM to that of
VCit-TFM in PBS, human serum, and mouse serum. All the test compounds demonstrated
complete stability in PBS and human serum for at least 24 h (Figure 7 and Figures 8-10 for
HPLC traces). However, EVCit-TFM and EVCit-BFM displayed much higher stability in
mouse serum in comparison to VCit-TFM, which only exhibited 20.9±1.4% of its original
concentration after 24 h of incubation compared to EVCit-TFM and EVCit- BFM's (71.3±2.5%
and 64.1±1.7% remaining after 24 h, respectively). It's possible that the increased steric bulk
introduced by the AG10 arm in EVCit-TFM is responsible for the slightly improved stability
of EVCit-TFM in comparison to EVCit-BFM. These findings provided evidence that the
EVCit tripeptide linker system plays the role that has been claimed for it in enhancing the
stability of ADCs. However, we found that there is still a significant level of hydrolysis in
mouse serum. This is in the contrast to data that was reported for ADCs, which showed that
the EVCit linker resulted in nearly complete stabilization in mouse serum after 24 h 40,42. We
then evaluated whether this increased stability of the EVCit linker would result in a reduction
in the toxicity produced by the premature release of the cytotoxic MMAE in mouse serum. We
also investigated whether this increased stability would have any influence on the cleavage by
cathepsin B.

43

Figure 7. Stability of EVCit-TFM and EVCit-BFM in comparison to VCit-TFM in (A) PBS,
B) human serum, and (C) mouse serum after 24 h of incubation at 37 ºC. Error bars indicate
mean ± s.d. (n=3). Statistical differences were determined using one-way ANOVA followed
by Tukey’s Post Hoc test indicated as (ns, not significant; *p ≤ 0.05; and ****p ≤ 0.0001).
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Figure 8. HPLC traces for the stability study of EVCit-TFM in PBS, human serum, and
mouse serum at 0 h and 24 h. HPLC traces are representative of assays performed in triplicate
(n=3).
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Figure 9. HPLC traces for the stability study of VCit-TFM in PBS, human serum, and mouse
serum at 0 h and 24 h. HPLC traces are representative of assays performed in triplicate (n=3).
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Figure 10. HPLC traces for the stability study of EVCit-BFM in PBS, human serum, and mouse
serum at 0 h and 24 h. HPLC traces are representative of assays performed in triplicate (n=3).
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4.2. EVCit-TFM and EVCit-BFM Displayed Lower In Vivo Toxicity than VCit-TFM in
CD-1 Mice.
We have demonstrated earlier that, lower dosages of 0.7 mg/kg (equivalent to 300
nmol/kg) of VCit-TFM exhibited no signs of toxicity. This was determined by observing the
change in body weight of mice after they were administered the test compounds

62

. We

investigated the toxicity of these molecules at a dose that was four times higher than previously
evaluated so that we could make a fair comparison between the toxicity of VCit-TFM and the
more stable EVCit-TFM and EVCit-BFM. The compounds were given at doses that were
considered to be equivalent (1200 nmol/kg each dose, once every 5 days for a total of 4 doses)
(Figure 11). Because of the instability of VCit-TFM in mouse blood, the mice experienced
severe toxicity, as evidenced by a loss of 20% of their body weight after receiving three doses
(Figure 11). This toxicity profile is comparable to the one that was caused by the administration
of the free MMAE, which served as a positive control cytotoxic agent and was given at a lower
dose of 0.4 mg/kg (equal to 600 nmol/kg). In contrast, neither the EVCit-TFM nor the EVCitBFM groups lost a substantial amount of body weight in comparison to the vehicle control
group (Figure 11). This investigation in CD-1 mice showed a strong correlation with what we
have found in vitro mouse serum stability assay (Figure 7) where we found that EVCit-TFM
and EVCit-BFM have higher serum stability than VCit-TFM. This supported the first part of
our hypothesis, which stated that the linker stability is critical for minimizing the toxicity
profile induced by the premature release of the cytotoxic MMAE from these SMDCs.
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Figure 11. Preliminary in vivo toxicity evaluation of VCit-TFM, EVCit-TFM, and EVCit-BFM
in CD-1 mice (20 animals; n=4 per group). Mice received equivalent single intraperitoneal
(i.p.) doses of vehicle control or test compounds: VCit-TFM (3.0 mg/kg equivalent to 1200
nmol/kg), EVCit-TFM (3.1 mg/kg equivalent to 1200 nmol/kg), EVCit-BFM (2.5 mg/kg
equivalent to 1200 nmol/kg), and MMAE (0.4 mg/kg equivalent to 600 nmol/kg) every 5 days
for a total of 4 doses. The body weights were recorded every 3 days for each animal. Each time
point indicates the mean % body weight change ± s.d. (n=4) from day 0. The significance of
the differences compared to the vehicle group was analyzed by one-way ANOVA followed by
Dunnett's post-hoc test indicated as (ns, not significant; ***p ≤ 0.001) and ****p ≤ 0.0001).
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4.3. Evaluation of the Binding Affinity and Selectivity towards TTR.
We evaluated the binding affinity and selectivity of EVCit-TFM towards human TTR,
which is crucial for its half-life extension. We have shown earlier that the binding affinity and
selectivity of VCit-TFM to TTR in human serum was translated into a superior
pharmacokinetic profile in rats and mice compared to its BFM counterpart

62

.

Using

fluorescence polarization assay, we found that the binding affinity of EVCit-TFM to human
TTR in buffer (Kd = 447.8 nM) was similar to that of VCit-TFM (Kd = 506.6 nM) (Figure 12A).
This is expected since the additional glutamic acid residue (~40 Å from AG10) is not in close
proximity to the TTR ligand (the distance from AG10 to the surface of TTR is ~20 Å). To
investigate the reason for the large decrease in binding affinity of the TFMs to TTR compared
to AG10 (Kd = 7.3 nM), we evaluated the effect of only attaching the linker (with 3 ethylene
glycol units) to AG10 (AG10-Linker; compound 11, Scheme 2). The binding affinity of AG10Linker to TTR (Kd = 74.3 nM) was lower than that of AG10 (Figure 12A) but higher than
TFMs. These data show that the larger the molecules attached to AG10 the lowers the binding
affinity of the AG10 conjugates to TTR. We next evaluated the selectivity of EVCit-TFM to
TTR in the presence of other serum proteins. This was evaluated using the well-established
fluorescent probe exclusion (FPE) selectivity assay

72,73

. In this competition assay, test

compounds compete for TTR in human serum with a selective covalent probe for TTR. The
FPE probe covalently modifies TTR in human serum resulting in fluorescence conjugate that
can be monitored over time. Molecules that bind selectively to TTR in serum decrease the
binding of the FPE probe to TTR, decreasing the fluorescence. In addition to selectivity, this
assay depends also on the relative affinity of the FPE probe and the test compound for the TTR
binding sites. We found that EVCit-TFM maintained excellent binding selectivity to TTR in
serum (TTR occupancy =67.5 ± 1.1%), which is similar to that of VCit-TFM (TTR occupancy
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63.9 ± 1.9%) (Figure 12B). The performance of the AG10-linker in the FPE assay (TTR
occupancy 80.7 ± 1.2%) was better than that of TFMs, which is due to the higher affinity for
TTR and potentially higher selectivity for TTR over other serum proteins. Notably, the
performance of both EVCit-TFM and VCit-TFM was better than that of the FDA-approved
TTR stabilizer, tafamidis (49.46 ± 1.19% TTR occupancy) 74. AG10 is another potent TTR
stabilizer in Phase 3 clinical trial and was used as a positive control (TTR occupancy 95.8 ±
1.8%) 68.

Scheme 2. Synthesis of AG10-Linker (compound 11)

We have also evaluated the binding affinity/selectivity of all test compounds to TTR
using the FPE assay in mouse serum. In vitro serum stability showed that 90% of EVCit-TFM
remains intact after 6 h incubation in mouse serum. We have shown earlier that 80% of VCitTFM remains intact after 6 h incubation in mouse serum 62. The trend of the FPE data in mouse
serum mirrored that in human serum. However, the probe binding to TTR, as indicated by
saturation in the fluorescence signal, is faster in mouse serum compared to human serum
(saturation at 1 h in mouse serum compared to 3 h in human serum) (Figure 12C).
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We have shown earlier that VCit-TFM displayed enhanced pharmacokinetic profile in
rats and mice compared to its BFM counterpart (while there was no measurable amount of
VCit-BFM after 4 h, VCit-TFM was still present even after 24 h) 62. Mouse TTR (conc. in
serum ∼5 μM) have ∼80% sequence homology with human TTR at the protein levels 75.
Importantly, the amino acids in the T4 binding sites of TTR, where EVCit-TFM binds, are
conserved between human and mouse. Therefore, we do not expect differences in the
binding of EVCit-TFM between human and mice TTR. The similarity in the binding affinity
and selectivity of EVCit-TFM and VCit-TFM to TTR in human serum indicates that the
EVCit-TFM will have an enhanced pharmacokinetic profile in mice similar to that of VCitTFM.
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Figure 12. The binding affinity and selectivity of EVCit-TFM and VCit-TFM to TTR in buffer,
human, and mouse serum. (A) The binding affinity of EVCit-TFM and VCit-TFM (0.01 µM
to 20 µM) to human TTR in buffer was performed using a fluorescence polarization assay. The
binding constant (Kd) values were calculated using the Cheng–Prusoff equation from IC50
values. Data represent the mean ± s.d. (n=3). (B) Fluorescence change caused by modification
of TTR in human serum (TTR concentration, ~5 μM) by covalent FPE probe monitored for 6
h in the presence of FPE probe alone (black circles) or probe and test compounds (colors; 10
μM). The lower the binding and fluorescence of the FPE probe, the higher the binding
selectivity of the compound to TTR. (C) Evaluation of test compounds in the FPE assay
performed in mouse serum.
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4.4. EVCit-TFM and EVCit-BFM Efficiently Release MMAE Following Cathepsin B
Cleavage in Buffer.
The results of the mouse serum stability assay made it clear that EVCit-TFM and
EVCit-BFM have greater stability than VCit-TFM. Next, we looked into whether or not this
improved stability would have an effect on the extent of cathepsin B hydrolysis that was
necessary for the cleavable linker.

Cathepsin cleavage assay is an in vitro enzymatic

experiment that was designed to mimic the in vivo cleavage of the linker by lysosomal
cathepsin B so that researchers could estimate the rate and extent of release of cytotoxic drug
from test compound. EVCit-TFM must be efficiently cleaved by cathepsin B within the
lysosomes of target cancer cells in order to release free cytotoxic payload MMAE to perform
its cytotoxic activity. After treating EVCit-TFM and EVCit-BFM with cathepsin B (isolated
from the human liver) in buffer (pH 5.5; optimal pH of cathepsin B, which is close to the pH
in the lysosome) at 37 ºC the stability of these two compounds was compared to VCit-TFM.
HPLC was utilized to monitor both the disappearance of the parent component and the release
of MMAE. The identity of the hydrolysis products was confirmed by LC-MS/MS evaluation.
Within 30 min of incubation of EVCit-TFM with cathepsin B, the parent compound
disappeared completely, and the release of MMAE was seen (Figure 13). VCit-TFM and
EVCit-BFM were significantly faster (within 15 min) in releasing MMAE compared to EVCitTFM. Although the increased serum stability of EVCit-TFM over VCit-TFM correlates with
the higher stability against cathepsin B cleavage, the data comparing EVCit-TFM to EVCitBFM suggest that the steric bulk of the TTR ligand arm in EVCit-TFM could play a role in the
enhanced stability against cathepsin B cleavage. In addition to this, we investigated the effect
that the cathepsin B activity of mice had on the hydrolysis of EVCit-TFM. Both human and
mouse cathepsin B exhibit comparable biochemical features, and the two enzyme's amino acid
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sequences are identical to an extent of 83% 76,77. The EVCit linker was successfully hydrolyzed
by mouse cathepsin B in EVCit-TFM, and the data presented by mouse cathepsin B were
comparable to the data displayed by human cathepsin B.
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Figure 13. EVCit-TFM efficiently releases MMAE after human cathepsin B cleavage. (A) The
EVCit tripeptide linker in EVCit-TFM is efficiently cleaved (within 30 min) by cathepsin B in
buffer. Spontaneous fragmentation of the para aminobenzylcarbamate intermediate resulted in
the formation of free MMAE and hydrolysis Fragment A. HPLC and LC−MS/MS analysis
confirmed the identity of hydrolysis products. (B-C) Similar results (with faster cathepsin B
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(Figure 13 Continued)
cleavage within 15 min in buffer) were obtained for cathepsin B hydrolysis of VCit-TFM and
EVCit-BFM. (D) MMAE was used as a control. The HPLC trace is representative of triplicate
experiments (n=3).
4.5. Evaluation of the Cytotoxicity of EVCit-TFM, EVCit-BFM, and VCit-TFM
Against Prostate Cancer Cells in the Presence and Absence of TTR.
Although we see that cathepsin B completely cleaves EVCit-TFM, the rate of MMAE
release was somewhat slower than that of VCit-TFM and EVCit-BFM. Next, we investigated
whether this slowness in cleavage of EVCit-TFM would have any effect on their cytotoxicity.
Comparing the cytotoxic effects of EVCit-TFM, EVCit-BFM, and VCit-TFM in LNCaP
(PSMA+) and DU145 (PSMA-) cells were used to evaluate the selective cytotoxic activity of
these three compounds (Figure 14). As a control for non-selective cytotoxicity, MMAE was
tested, and it was found to be cytotoxic irrespective of cell lines (Figure 14A). To determine
whether or not TTR has any influence on the targeting of LNCaP (PSMA+) cells, we
additionally tested the cytotoxicity of each compound in the presence of TTR at a concentration
of 1 µM. Although EVCit-TFM was slightly slower in releasing MMAE in the cathepsin B
cleavage assay, the targeted cytotoxicity towards LNCaP (PSMA+) cells was not very different
from what we found for VCit-TFM (IC50 = 0.98 nM and 1.06 nM in the presence and absence
of TTR respectively). For EVCit-TFM, the cytotoxicity towards LNCaP (PSMA+) cells was
found to be similar in the presence (IC50 = 1.19 nM) and absence (IC50 = 1.02 nM) of TTR
(Figure 14B). In addition, the findings demonstrated that TTR does not impede the targeting
of the test compounds or the efficient release of MMAE from within (PSMA+) cells. Testing
the activity of EVCit-TFM against DU145 (PSMA-) prostate cancer cell line provided further
confirmation of the specific cytotoxicity of the compound. We found that the activity of EVCitTFM against DU145 (PSMA-) cells is 400-fold less cytotoxic compared to the activity against
LNCaP (PSMA+) cells. This finding implies that EVCit-TFM has the ability to differentiate
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between nontargeted/normal cells and cancer cells (IC50 = 1.02 nM). It is interesting to note
that the cytotoxicity of EVCit-TFM against DU145 (PSMA-) cells (IC50=1281 nM) was
reduced by a factor of three when TTR was present compared to when it was absent. A similar
trend was found for VCit-TFM too. There was no effect of TTR on the selective cytotoxicity
of EVCit-BFM because it doesn’t have the TTR ligand arm (Figure 14D). The effect of TTR
on lowering the cytotoxicity against PSMA- cells was confirmed by performing the
cytotoxicity experiment in HeLa cells (PSMA-). The IC50 value for EVCit-TFM was 259.26
nM in the absence of TTR and 815.83 nM in its presence (Figure 15). These findings lend
credence to our previously published findings, which revealed that TTR can, in fact, sequester
TFMs in cells that are devoid of targeted PSMA receptors, hence reducing the toxicity towards
healthy cells 62.
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Figure 14. Selective cytotoxicity of EVCit-TFM, VCit-TFM, and EVCit-BFM against LNCaP
(PSMA+) versus DU145 (PSMA−) cells. MTT cell proliferation assay was used to determine
the selective cytotoxicity of test compounds against LNCaP (PSMA+) and DU145 (PSMA-)
cell lines in the absence and presence of TTR. (A) MMAE showed effective non-selective
cytotoxicity towards both LNCaP (PSMA+) and DU145 (PSMA-) cells. (B) EVCit-TFM and
(C) VCit-TFM demonstrated selective cytotoxicity against LNCaP (PSMA+) compared to
DU145 (PSMA-) cell lines and showed similar trends in terms of lower cytotoxicity in the
presence of TTR. (D) EVCit-BFM was selective against LNCaP (PSMA+) compared to DU145
(PSMA-) cell lines; however, the cytotoxic activity against DU145 (PSMA-) was similar in the
absence and presence of TTR. All time points are expressed as means ± s.d. (n=5).
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Figure 15. Evaluating the effect of TTR on enhancing the selectivity of MMAE, EVCit-TFM,
VCit-TFM, and EVCit-BFM against the (PSMA-) HeLa cell line. (A) MMAE displayed nonselective cytotoxicity. (B) EVCit-TFM and (C) VCit-TFM displayed ~3-fold lower
cytotoxicity towards HeLa cells in the presence of TTR. (D) There was no effect of TTR on
the cytotoxicity profile of EVCit-BFM. All the time point is expressed as means ± s.d. (n=5).
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4.6. Dose-escalation Study for EVCit-TFM and EVCit-BFM in Mice.
Our results show that multiple doses of EVCit-TFM and EVCit-BFM (dosed at 1,200
nmol/kg) can be given to mice without affecting their body weight (Figure 11). VCit-TFM, on
the other hand, was toxic at equivalent doses of 1,200 nmol/kg. As a result, we decided to only
evaluate the efficacy of EVCit-TFM and EVCit-BFM. We performed a dose-escalation study
to evaluate the maximum tolerated dose (MTD) of EVCit-TFM that will be used for the
xenograft efficacy studies in mice (measured by change in the body weight of mice). In our
study, we used EVCit-BFM as a control for a typical bifunctional SMDC. Docetaxel was
introduced as a positive control for standard non-targeted chemotherapy for metastatic
castration-resistant prostate cancer (mCRPC) 78. For this study, 9 groups (n=4) of Nu/Nu male
mice (same mouse species/breed used in the xenograft study) received a single intraperitoneal
(i.p.) dose of vehicle or docetaxel (10 mg/kg, 20 mg/kg, and 40 mg/kg) every 5 days for a total
of 4 doses (Figure 16). Mice's body weights were measured in every three days for a total of
21 days. Docetaxel at 10 mg/kg (equivalent to 12,000 nmol/kg; a dose reported in similar
xenograft studies with prostate cancer cells) showed no toxicity 79,80. However, all mice treated
with the higher docetaxel doses (20 mg/kg and 40 mg/kg) had a significant decrease in body
weight, indicating significant toxicity. As a result, the 10 mg/kg docetaxel dose was chosen
for the in vivo efficacy study. Our preliminary toxicity data with CD-1 mice (Figure 11)
revealed that EVCit-TFM was not toxic at a dose of 3.1 mg/kg (1,200 nmol/kg). As a result,
the starting dose for EVCit-TFM in the dose-escalation study was 3.1 mg/kg. EVCit-BFM was
also given an equivalent starting dose (2.5 mg/kg; equivalent to 1,200 nmol/kg). In comparison
to vehicle-dosed mice, increasing the EVCit-TFM dose to 6.2 mg/kg resulted in a lower
increase in body weight. On the other hand, EVCit-BFM, was well tolerated at 5 mg/kg (2,400
nmol/kg), a dose twice as high as EVCit-TFM.

Increasing the EVCit-BFM dosing
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concentration to 10 mg/kg (4,800 nmol/kg) resulted in molecule precipitation, necessitating an
increase in the volume of the dosing solution to the maximum tolerated volume for i.p. injection
81

. Because of the solubility issue, we were unable to test higher doses of EVCit-BFM than 10

mg/kg. Because EVCit-TFM and EVCit-BFM have similar stability in mouse serum (60-70%
remaining after 24 h), we hypothesized that EVCit- BFM's lower toxicity was due to its shorter
half-life than EVCit-TFM (i.e., lower exposure to free MMAE since EVCit-BFM cannot bind
to TTR and therefore is cleared rapidly). The higher toxicity of EVCit-TFM due to prolonged
exposure in mice could be analogous to the case of ADCs, where prolonged exposure often
results in toxicity due to payload release in serum 40,42. As a result, the doses of EVCit-TFM
of 3.1 mg/kg (1,200 nmol/kg) and EVCit-BFM of 10 mg/kg (4,800 nmol/kg) were chosen for
the in vivo efficacy study. This ensures that the efficacy data observed are due to the targeting
of these intact conjugates rather than collateral toxicity caused by prematurely released
MMAE.
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Figure 16. Dose-escalation study for EVCit-TFM, EVCit-BFM, and docetaxel in male athymic
nude mice (36 animals; n=4 per group). Mice received vehicle or a single dose of EVCit-TFM
3.1 mg/kg (equivalent to 1,200 nmol/kg), or 6.2 nmol/kg (equivalent to 2,400 nmol/kg); EVCitBFM 2.5 mg/kg (equivalent to 1,200 nmol/kg), 5.0 mg/kg (equivalent to 2,400 nmol/kg), or 10
mg/kg (equivalent to 4,800 nmol/kg); docetaxel 10 mg/kg (equivalent to 12,000 nmol/kg), 20
mg/kg, or 40 mg/kg; every 5 days for 15 days (a total of 4 doses). The body weights were
recorded every 3 days for each mouse. Each time point indicates the mean % body weight
change from day 0 ± s.d. (n=4). The significance of the differences compared to the vehicle
group was analyzed by one-way ANOVA followed by Dunnett's post-hoc test indicated as (ns,
not significant; ***p ≤ 0.001; and ****p ≤ 0.0001).
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4.7. EVCit-TFM has Enhanced Antitumor Activity in Xenograft Mouse Model of
Human Metastatic Prostate Cancer
In nude mice bearing the LNCaP (PSMA+) xenograft prostate cancer model, we tested
the antitumor activity of EVCit-TFM, EVCit-BFM, and docetaxel (Figure 17). The antitumor
activity was assessed by measuring the change in tumor size over time and the delay in tumor
relapse after dosing was discontinued. In comparison to other treatment groups, our data
showed that EVCit-TFM effectively suppressed tumor growth and delayed tumor relapse in
mice (Figure 17A). Importantly, mice given EVCit-TFM continued to gain weight throughout
the study (Figure 17B). These findings supported our hypothesis that improving the stability
of the cathepsin B cleavable linker would improve EVCit- TFM's safety profile while also
increasing its antitumor efficacy in vivo. At 48, 69, and 100 days, mice in the vehicle, docetaxel,
and EVCit-BFM groups reached the defined endpoint (animals were sacrificed when the tumor
volume reached about 2000 mm3), respectively. While the 10 mg/kg dose of docetaxel used in
our study was not toxic, it was not as effective as the other two targeted molecules. The loss
of body weight in docetaxel-treated mice is due to tumor burden, which is comparable to the
vehicle-treated group. In contrast, all mice in the EVCit-TFM group survived the entire study
(100 days) (Figure 17C). Importantly, in comparison to a 4-fold higher molar dose of EVCitBFM (4,800 nmol/kg) and a 10-fold higher molar dose of docetaxel (12,000 nmol/kg), EVCitTFM (1,200 nmol/kg) significantly delayed tumor relapse (for at least 2 months after the last
dose) (Figure 17A).
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Figure 17. Antitumor efficacy of EVCit-TFM, EVCit-BFM, and docetaxel in LNCaP
(PSMA+) xenograft mouse models of metastatic prostate cancer. Xenograft mouse models
(n=7 per group) with tumors (100-150 mm3 in size) received vehicle or multiple doses of
EVCit-TFM (3.1 mg/kg; equivalent to 1,200 nmol/kg), EVCit-BFM (10 mg/kg; equivalent to
4,800 nmol/kg), and docetaxel 10 mg/kg (equivalent to 12,000 nmol/kg). (A) Progression of
tumor volume over time. Black arrows indicate the dosing regimen (i.p. injections every 5 days,
for a total of 7 doses). The vertical dotted line divided the treatment period and observed period
while the horizontal dotted line indicates the defined endpoint of 2000 mm3 (mice were
sacrificed when the tumor volume reached ~2000 mm3). Each point represents the average (±
s.d.) tumor volume (mm3) of each group. The mice with a defined endpoint were euthanized,
and their terminal tumor volume was used for mean tumor volume calculation until all the mice
of that group reached the endpoint. (B) Data represent mean (± s.d.) % body weight changes in
each group from the beginning of treatment. (C) The Kaplan-Meier survival plot shows how
long the mice in each group survived without reaching the defined endpoint. The significance
between EVCit-TFM and other comparing groups in reaching the endpoint was measured by
the p-value obtained through Log-rank (Mantel-Cox) test indicated as ***p ≤ 0.001.
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CHAPTER 5: DISCUSSION

Small-format SMDCs have several advantages over traditional non-targeted therapeutic
agents. However, the poor pharmacokinetic profile of these molecules remains an important
issue that is yet to be resolved. Our lab has previously reported that the pharmacokinetic profile
of bifunctional SMDCs can be improved by conjugation with the hydrophilic transthyretin
ligand, AG10 (forming trifunctional molecules, TFMs). The Valine-Citrulline linker instability
of the first generationTFM SMDCs in mouse serum hampered the evaluation of higher doses
of these TFMs due to the premature release of cytotoxic payload extracellularly in blood.
Therefore, strategies that enhance the stability of the cleavable linkers in SMDCs in mouse
serum could bring flexibility in evaluating higher doses. Tripeptide cleavable linker (Glutamic
Acid-Valine-Citrulline) EVCit was reported to enhance the stability of this class of linkers
when used in ADCs. We hypothesized that the EVCit linker could also be utilized to enhance
the stability of SMDCs in mouse blood. To the best of our knowledge, no one has utilized this
linker for smaller format SMDC. We designed and synthesized a new generation of SMDC
TFMs and compared the stability of these molecules with SMDCs that utilized VCit linker.
We found that the new EVCit linker increases the stability (at least 3-fold) in mouse serum
while showing similar stability in human serum compared to VCit linker containing SMDC.
We then evaluated whether this in vitro stability could be translated into in vivo safety profile.
The EVCit containing SMDCs showed superior safety profile at a higher dose. Therefore, the
first part of our hypothesis was achieved through this study. We then investigated whether this
enhanced in vitro stability and in vivo safety would compromise the efficacy of these
molecules. For the efficacy to be superior, we emphasized on the longer exposure to the tumor
cell provided by our transthyretin (TTR) drug delivery system. The binding affinity and
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selectivity of EVCit-TFM & VCit-TFM to TTR in buffer and human serum was confirmed and
found to be similar for both compounds. Our data also showed that the SMDC TFM can
effectively release its payload after reaching the target site inside cancer cells. This was
confirmed by performing an in vitro cathepsin B cleavage assay which mimics the in vivo
release of payload from the TFMs. Although the lead molecule EVCit-TFM is slower in
releasing MMAE after cathepsin B cleavage, the release of MMAE was complete within 30
min. In contrast, the release of MMAE form VCit-TFM and EVCit-BFM was complete within
15 min. We then investigated whether this slower release has any impact on cytotoxicity
against targeted cancer cells. We found that the potency of EVCit-TFM (evaluated by MTT
cell viability assay) is similar to VCit-TFM which released the MMAE payload much faster in
cathepsin assay. As we have observed in previous studies, TTR indeed sequesters the TFMs
from diffusing into the non-targeted cells. Finally, we evaluated the efficacy of EVCit-TFM
and EVCit-BFM and compared them to docetaxel (a positive control for standard treatment
option utilized in the clinic for prostate cancer). The maximum tolerated dose for the test
compounds was determine and the efficacy study was performed in a xenograft mouse model
of prostate cancer that we generated. We found EVCit-TFM is superior both in terms of
efficacy and safety compared to EVCit-BFM and the positive control, docetaxel. These results
demonstrated the success of our TTR drug delivery system in enhancing the safety and efficacy
of SMDCs containing the stable EVCit-Linker.
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CHAPTER 6: CONCLUSION

We reported for the first time in this study the effect of stabilizing the cathepsin B
cleavable linkers on the toxicity and efficacy of TFM-based SMDCs. While the EVCit linker
has been extensively studied for ADCs stabilization, no data for SMDCs has been published.
Our research found that replacing the VCit dipeptide linker (found in first generation VCitTFMs) with the EVCit tripeptide linker resulted in a more stable EVCit-TFM in mouse serum.
While the EVCit linker improved the stability of BFMs and TFMs based SMDCs in mouse
serum (~60% & ~70% remaining after 24 h), this linker has demonstrated much higher stability
in ADCs (100% remaining after a few days)

40,42

. Furthermore, incorporation of the EVCit

tripeptide linker into ADCs resulted in conjugates that were more sensitive to cathepsin B
cleavage than conjugates with the VCit dipeptide linker 40. In contrast, EVCit-TFM was found
to be more stable against cathepsin B cleavage than VCit-TFM and EVCit-BFM. These
findings suggest that the stability of cathepsin B should be investigated for each individual
molecule. Nonetheless, increasing the linker's stability in SMDCs resulted in lower toxicity in
mice. This enabled us to increase the dose of EVCit-TFM, resulting in improved in vivo
efficacy over docetaxel in a prostate cancer xenograft mouse model. By comparing the efficacy
of EVCit-TFM to that of a stabilized typical bifunctional SMDC (i.e., EVCit-BFM), we found
that the EVCit-increased the circulation half-life of EVCit-TFM due to binding to TTR which
is a major factor in the observed enhanced efficacy. To the best of our knowledge, this is the
first study to show that the tripeptide EVCit linker improves the serum stability and in vivo
efficacy of small size SMDC targeting prostate cancer and potentially other cancers.
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CHAPTER 7: EXPERIMENTAL SECTION

7.1. Method
7.1.1. Materials and Reagents
Prealbumin from human plasma (human TTR) (#P1742) and human serum (#H4522)
was purchased from Sigma. Mouse Balb C Serum (#IMSBCSER) was purchased from
Innovative Research. Human prostate carcinoma cell lines LNCaP (PSMA+) (ATCC CRL1740) and DU145 (PSMA-), (ATCC HTB-81) were purchased from American Type Culture
Collection (ATCC). Cathepsin B from the human liver was purchased from Calbiochem, EMD
Millipore Corp (#219362-50UG). Recombinant Mouse Cathepsin B Protein derived from
Baculovirus was purchased from Novus Biologicals™ (#NBP25308410UG).
7.1.2. Chemical Synthesis and HPLC Purity Analysis.
The synthesis of EVCit-TFM and EVCit-BFM is described in Scheme 1. The final
compound synthesized following this scheme has uniform composition and high purity
(>95%); the detailed description of the synthesis is given below, and purity analysis can be
found in the supporting information 43. We reported the synthesis of VCit-TFM earlier 62.
7.1.3. Materials for Chemical Synthesis.
For all the reactions, inert conditions were maintained by employing argon or nitrogen.
Reaction solvents were ACS grade and purchased from Fisher. % yields were calculated
chromatographically and spectroscopically unless otherwise noted. Reagents purchased from
Aldrich and Fisher were directly used for reactions without further purification. Reactions
were followed by thin-layer chromatography (TLC) performed on EMD Millipore® silica gel
60 coated with fluorescent indicator F254 TLC plates (cat # 5737-7). UV light and an iodine
chamber were used for visualization. Normal phase flash column chromatography was carried
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out using Combi Flash® Rf+ Lumen instrument (Teledyne ISCO) with High-Performance
Silica Flash Column (RediSep® Rf+ Gold), 1H NMR and 13C NMR spectra were recorded on
a Jeol JNM−ECA600 spectrometer and calibrated using residual undeuterated solvent as an
internal reference. Coupling constants (J) were expressed in Hertz. LC-MS/MS analysis was
performed on Agilent 1200 HPLC coupled with a triple quadrupole mass spectrometer (AB
SCIEX API 3000™) 43.
7.1.4. Analytical and Preparative HPLC Systems for Analysis and Purification of TFMs
and BFMs.
The analysis of key compounds’ purity (>95% for all compounds) was performed using
C18 and C4 reverse-phase HPLC columns on an Agilent 1100 series HPLC system connected
to a diode array detector operating between the UV ranges of 200 – 400 nm and quantified
using Agilent Chemstation software. The HPLC analysis was performed on a Waters™
XBridge C18 column (2.1 X 150 mm, 5 μm) or a Waters™ Symmetry 300 C4 column (2.1 X
150 mm, 5 µm), eluting at 0.5 mL/min, at ambient temperature upon injection of 50 μL of each
sample to obtain the chromatogram at 254 nm UV absorbance. The purification was performed
on a Waters Delta 600 HPLC system connected to a photodiode array detector operating
between the UV ranges of 210 – 600 nm, using Waters Masslynx V4.1 software. The HPLC
purification was performed using an XBridgeTM Prep C18 Column (10 x 100 mm, 5 μm) at
ambient temperature upon injecting 5 mL of each sample to obtain the chromatogram at 254
nm UV absorbance. For both analytical and preparative mobile phase was composed of solvent
A consisting of acetonitrile-water (5:95, v/v) containing 0.1% formic acid and solvent B
consisting of acetonitrile-water (95:5, v/v) containing 0.1% formic acid and delivered at a flow
of 0.5 mL/min and 2.0 mL/min respectively. The HPLC program was a gradient separation
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increasing linearly from 0-100 % solvent B at 0-20 min followed by isocratic 100%B until 30
min, then back to 0% B by 32 min 43.
7.1.5. Chemical Synthesis procedures:

((S)-5-(tert-butoxy)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-5
oxopentanoyl)-L-valine (4). (2 g, 1.06 mmol, 1equiv.) of H-Valine-2-Chlorotrityl resin was
allowed to swell in 25 mL anhydrous dichloromethane (DCM) for 30 min in a 250 mL
peptide synthesizer. The DCM was drained. The coupling cocktail was prepared by mixing
Fmoc-L-glutamic acid γ-tert-butyl ester hydrate (1.88 g, 4.24 mmol, 4 equiv.), 1[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate (HATU) (1.61 g, 4 eq, 4.24 mmol) and N,N-diisopropylethylamine
(DIPEA) ( density 0.74 g/cm3, 1.1 mL, 6 equiv.) in 20 mL anhydrous DMF. The mixture was
activated for 5 min before adding to the resin. The mixture was gently shaken for 3 h. The
Kaiser test was utilized to confirm the completion of the coupling. The coupling cocktail
solution was drained, and the resin was washed with DMF (3×20 mL) and DCM (3×20 mL).
The same protocol was followed for all future washings. Deprotection of the Fmoc
protecting group was performed by shaking the resin for 30 min with 20% piperidine in
DMF, confirmed by Kaiser Test, and washed. The following coupling was performed by 6Maleimidohexanoic acid N-hydroxysuccinimide ester (1.3 g, 4.24 mmol, 4 equiv.) and
DIPEA (density 0.74, 1.85 mL, 10 equiv.) in a final volume of 20 mL for overnight. The
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solution was drained, and the completion of the reaction was confirmed by Kaiser test,
followed by washing the resin. Initially, 10% trifluoroacetic acid (TFA) in DCM was applied
to cleave the compound from resin; however, the resulting cleaved residue contained
mixtures of compound which was difficult to separate and showed evidence of loss of the γtert-butyl protecting group. Finally, 20% 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) in DCM
for 2 h was used for cleaving the product from resin because of its superior purity and
retainment of the γ-tert-butyl protecting group intact in the cleaved compound. The cleaved
compound was concentrated under reduced pressure to give compound 4 (420 mg; 80%
yield), which was used in the next step without further purification. 1H-NMR (CD3OD, 600
MHz) δ 6.70 (s, 2H), 4.33 (dd, 1H, J = 8.6, 5.9 Hz), 4.22 (d, 1H, J = 5.4 Hz), 3.40 (t, 2H, J =
7.1 Hz), 3.22-3.21 (m, 2H), 2.26-2.23 (m, 1H), 2.14 (t, 2H, J = 7.5 Hz), 1.91-2.00 (m, 1H),
1.73-1.82 (m, 1H), 1.57-1.46 (m, 4H), 1.36 (s, 9H), 1.22 (dd, 2H, J = 15.5, 8.0 Hz), 0.88 (d,
3H, J = 2.3 Hz), 0.87 (d, 3H, J = 2.3 Hz); 13C-NMR (150 MHz, CD3OD) δ 176.2, 174.6,
174.2, 174.1, 172.7, 135.5, 82.0, 59.1, 53.9, 49.6, 49.4, 49.3, 49.1, 49.0, 48.9, 48.7, 38.5,
36.7, 32.8, 31.9, 29.4, 28.5, 28.4, 28.4, 27.5, 26.5, 19.7, 18.3. ESI-MS (Figure 18). Exact
mass calcd for C24H37N3O8 [M+H] + 496.57; [M+Na]+ 518.57. Found: 496.73, 518.71

tert-butyl

(S)-4-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-5-(((S)-1-

(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-
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oxobutan-2-yl)amino)-5-oxopentanoate (6). Compound 4 (390 mg, 0.79 mmol, 1equiv.) was
activated by reacting with N-Hydroxysuccinimide (NHS) (108.7 mg, 0.94 mmol, 1.2 equiv.)
in presence of N,N′-Dicyclohexylcarbodiimide (DCC) (density 1.32 g/cm3, 346 µL, 2.22
mmol, 2.8 equiv.) in 5 mL THF. The reaction mixture was stirred overnight. The resulting
white solid was filtered out and washed by DCM, while the liquid fraction contained the desired
compound as confirmed by TLC. The soluble fraction was concentrated under reduced
pressure, re-dissolved in 5 mL DMF, and DIPEA (345 µL, 2.5 equiv) was added. Compound
5 (177.6 mg, 0.63 mmol, 0.8 equiv.) was dissolved in 5 mL anhydrous DMF and added to the
reaction mixture to give a clear yellowish solution 82. After 12 h, the reaction was diluted with
100 mL ethyl acetate (EtOAc) and washed with brine 3x50 mL. The EtOAc fraction was dried
over sodium sulfate and the resulting solid residue was purified by flash column
chromatography using 5-15% MeOH in DCM to give compound 6 (207 mg; 43.3% yield) as a
white solid. 1H-NMR (CD3OD, 600 MHz) δ 7.45 (d, 2H, J = 8.6 Hz), 7.20 (d, 2H, J = 8.7
Hz), 6.69 (s, 2H), 4.45-4.42 (m, 3H), 4.31 (dd, 1H, J = 8.9, 5.7 Hz), 4.13 (d, 1H, J = 7.1 Hz),
3.38 (t, 2H, J = 7.2 Hz), 3.22-3.21 (m, 3H), 3.13-3.08 (m, 1H), 3.03-2.99 (m, 1H), 2.14 (t, 2H,
J = 7.5 Hz), 2.01-1.93 (m, 2H), 1.83-1.75 (m, 2H), 1.69-1.63 (m, 1H), 1.56-1.42 (m, 6H), 1.34
(s, 9H), 1.24-1.18 (m, 2H), 0.86 (t, 6H, J = 6.7 Hz); 13C-NMR (150 MHz, CD3OD) δ 176.4,
174.2, 174.1, 173.7, 172.7, 172.4, 162.4, 138.9, 138.8, 135.5, 128.7, 121.3, 82.0, 65.0, 60.4,
55.1, 54.2, 50.0, 49.6, 49.4, 49.3, 49.1, 49.0, 48.9, 48.7, 38.5, 36.7, 32.9, 32.1, 30.7, 29.4, 28.5,
28.3, 27.9, 27.5, 26.5, 19.9, 18.9. ESI-MS: Exact mass calcd for C37H55N7O10 [M+H]+ 758.4;
[M+Na]+ 780.4; [M+Na]2+ 390.2; [M+H+Na]+ 781.4. Found: 758.85, 780.90, 391.56, 781.95
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tert-butyl(S)-5-(((S)-1-(((S)-1-((4-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3oxopropyl)pyrrolidin-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13dioxa-4,7,10-triazatetradecyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1oxobutan-2-yl)amino)-4-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-5oxopentanoate (7). Compound 6 (160 mg, 0.21 mmol, 1 equiv.) was activated by bis (4nitrophenyl) carbonate (128.37 mg, 0.42 mmol, 2 equiv.) in 3 mL DMF where DIPEA (91.7
µL, 2.5 equiv.) was added to the solution. After 2 h, the reaction was concentrated under
reduced pressure. The dried yellowish solid was triturated by 20% ethyl acetate in hexane;
filtered out the liquid. After repeating the process multiple times, TLC showed that most of
the impurity was removed, resulting in 145 mg (74.8% yield) of pure off-white solid compound
which was used in the next step without further purification. 120 mg (0.13 mmol, 1 equiv.) of
activated compound 6, MMAE (62.2 mg, 0.086 mmol, 0.6 equiv.), 1-Hydroxybenzotriazole
(HOBT) (3.51 mg, 0.13 mmol, 0.2 equiv.) was mixed in 2.5 mL of DMF. After 2 min, 200 µL
of pyridine was added to the solution and the reaction was monitored by reverse-phase HPLC.
The reaction was complete after 24 h. The reaction mixture was concentrated under reduced
pressure and purified by semi-preparative RP-HPLC to give compound 7 (51 mg: 39.5% yield).
ESI-MS:

Exact mass calcd for C77H120N12O18 [M+Na]+ 1524.87; Found: 1524.4. The

deprotection of compound 7 (37 mg, 0.025 mmol, 1 equiv) was performed by adding a mixture
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of 200 µL TFA in 800 µL DCM at 0 °C for 2 h. The reaction progress was monitored again
by RP-HPLC.

The reaction mixture was quenched with saturated NH4OH (300 µL),

concentrated under reduced pressure, and dried under high vacuum, and the concentrate was
used in the next steps without further purification.

Synthesis of VCit-TFM (1). Compound 1 has been synthesized as reported earlier 62.
97% purity by HPLC. 1H-NMR (CD3OD, 600 MHz) δ 7.71 (s, 1H), 7.49 (d, 2H, J = 6.1 Hz),
7.29-7.18 (m, 6H), 7.12-7.03 (m, 3H), 6.59 (s, 1H), 5.09-5.05 (m, 2H), 5.00-4.97 (m, 1H), 4.584.51 (m, 2H), 4.48-4.41 (m, 4H), 4.23 (d, 1H, J = 8.6 Hz), 4.18-4.06 (m, 5H), 3.93-3.87 (m,
5H), 3.83-3.77 (m, 4H), 3.62-3.51 (m, 8H), 3.46-3.28 (m, 5H), 3.17-2.92 (m, 19H), 2.86-2.78
(m, 4H), 2.61 (t, 2H, J = 7.3 Hz), 2.55-2.46 (m, 2H), 2.41-2.26 (m, 5H), 2.23 (s, 6H), 2.19-2.01
(m, 7H), 1.99-1.64 (m, 13H), 1.59-1.28 (m, 22H), 1.24-1.14 (m, 4H), 1.09-1.02 (m, 6H), 0.980.59 (m, 27H). ESI-MS: Exact mas calcd for C121H188N22O31S [M+H]+ 2478.4; [M+H]2+
1239.7; Found: 2477.7, 1240.8
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Synthesis of EVCit-TFM (2). To a solution of compound 7 (35.6 mg, 0.025 mmol, 1
equiv.) in anhydrous DMF (1.5 mL) and triethylamine (45 µL) was added a solution of
compound 8 (57 mg, 0.049 mmol, 2 equiv.) in DMF (0.5 mL)62. The reaction was stirred at
room temperature for 5 h after which HPLC analysis showed that the reaction was complete.
The solution was concentrated under reduced pressure and purified by semipreparative RPHPLC to afford EVCit-TFM (2) (21 mg; 33% yield); 95% purity by HPLC; tR (column) (C4)
= 11.54 min; tR (C18) = 17.25 min. 1H-NMR (CD3OD, 600 MHz) δ 8.42 (s, 1H), 7.78 (d, 1H,
J = 6.5 Hz), 7.51 (d, 2H, J = 7.5 Hz), 7.30-7.16 (m, 5H), 7.13-7.09 (m, 1H), 7.03 (s, 2H), 6.47
(s, 1H), 5.26-5.01 (m, 2H), 4.97 (s, 1H), 4.59-4.56 (m, 1H), 4.46-4.42 (m, 3H), 4.31-4.28 (m,
1H), 4.18-4.04 (m, 5H), 3.97-3.90 (m, 2H), 3.84-3.77 (m, 5H), 3.63-3.46 (m, 9H), 3.40-3.31
(m, 5H), 3.18-2.94 (m, 14H), 2.87-2.82 (m, 3H), 2.58 (s, 1H), 2.53-2.48 (m, 3H), 2.41-2.36 (m,
2H), 2.30-2.21 (m, 4H), 2.15-1.97 (m, 14H), 1.86-1.76 (m, 7H), 1.72-1.64 (m, 5H), 1.58-1.27
(m, 21H), 1.20 (s, 19H), 1.08-1.02 (m, 6H), 0.96-0.65 (m, 27 H). ESI-MS: Exact mass calcd
for C126H195N23O34S [M+H]+ 2608.13; [M+2H]2+ 1304.1; [M+3H]3+ 869.3. Found: 2609,
1305.9, 870.8
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Figure 18. HPLC traces of EVCit-TFM in C18 and C4 column (>95% purity).
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Synthesis of EVCit-BFM (3). To a solution of compound 7 (35.6 mg, 0.025 mmol, 1
equiv.) in anhydrous DMF (1.5 mL) and triethylamine (45 µL) was added a solution of
compound 9 (30.5 mg, 0.049 mmol, 2 equiv.) in DMF (0.5 mL) 62. The reaction was stirred at
room temperature for 5 h after which HPLC analysis showed that the reaction was complete.
The solution was concentrated under reduced pressure and purified by semipreparative RPHPLC to afford EVCit-BFM (3) (16 mg; 30% yield); (99% purity by HPLC): tR (column) (C4)
= 12.3 min; tR (C18) = 18.1 min. 1H-NMR (CD3OD, 600 MHz) δ 7.50 (d, 2H, J = 7.2 Hz),
7.30-7.19 (m, 6H), 7.13-7.11 (m, 1H), 5.12-5.06 (m, 2H), 4.98 (dd, 1H, J = 12.5, 3.5 Hz), 4.584.52 (m, 1H), 4.48-4.38 (m, 2H), 4.33-4.30 (m, 1H), 4.23 (dd, 1H, J = 8.5, 5.0 Hz), 4.19-4.08
(m, 4H), 3.86-3.83 (m, 1H), 3.78 (d, 1H, J = 9.1 Hz), 3.65-3.53 (m, 3H), 3.51-3.38 (m, 3H),
3.34-3.30 (m, 2H), 3.18 (s, 1H), 3.15-2.99 (m, 9H), 2.93-2.83 (m, 4H), 2.60-2.48 (m, 4H), 2.432.27 (m, 8H), 2.24-1.96 (m, 9H), 1.87-1.61 (m, 7H), 1.59-1.39 (m, 14H), 1.36-1.20 (m, 15H),
1.09-1.02 (m, 6H), 0.98-0.66 (m, 26H). [ESI-MS: Exact mass calcd for C99H153N17O28S
[M+H]+ 2061.46; [M+2H]2+ 1032.0, [M+Na]+ 2084.46; Found: 2061.9, 1032.0 , 2083.7

78

Figure 19. HPLC traces of EVCit-BFM in C18 and C4 columns (>95% purity).
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Synthesis of AG10-Linker (11). Compound 10 was synthesized as reported earlier 62.
Compound 10 (292 mg, 0.451 mmol, 1 equivalent) was treated with a mixture of TFA and
DCM, (1:4 ratio) (5 mL) and the reaction was stirred at room temperature for 2 h. The solution
was concentrated under reduced pressure and purified by preparative HPLC to afford
compound 11 (222 mg, 90% yield); 1H NMR (CD3OD, 600 MHz) δ 7.02 (d, 2H, J = 2.4 Hz),
6.46 (t, 1H, J = 2.4), 3.89 (t, 2H, J = 6 Hz), 3.80 (t, 2H, J = 6 Hz), 3.67-3.64 (m, 2H), 3.583.54 (m, 6H), 3.3-3.26 (m, 2H), 3.12-3.09 (m, 2H), 2.95-2.91 (m, 2H), 2.47 (t, 2H, J = 7.2 Hz),
2.03 (s, 6H), 1.84-1.78 (m, 2H), 1.72-1.66 (m, 2H), 1.65-1.59 (m, 2H), 1.47-1.41 (m, 2H), 1.391.33 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 10.76, 20.04, 26.84, 27.26, 27.42, 30.13, 31.06,
48.60, 51.92, 67.15, 67.89, 69.06, 71.24, 71.63, 71.65, 106.17, 108.83, 108.91, 115.46, 138.07,
143.46, 161.51, 169.39. HRMS (DART) m/z: calcd for C27H42N6O6 + H+ 547.3244; found
547.3244 (M + H)+.
7.2. Experimental Animals.
All the animal procurement, housing, food, water, tumor inoculation, tumor volume
measurement, and body weight measurement, and euthanasia were conducted in accordance
with National Institutes of Health guidelines for the care and use of live animals, which were
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
the Pacific 43.
7.3. Stability of EVCit-TFM, EVCit-BFM, and EVCit-TFM
The stability of EVCit-TFM, EVCit-BFM, and VCit-TFM in PBS, human, and mouse
serum was evaluated at 0 h and 24 h. The stability of EVCit-TFM at 6 h was also evaluated.
All the test compounds were incubated in PBS, human, and mouse serum at 37 ºC. The
experiments were performed in triplicate. At 0 h and 24 h, aliquots of each sample (100 µL)
were quenched by 2 volumes (200 µL) of HPLC solvent B (acetonitrile-water; 95:5 v/v, 0.1%
formic acid), vortexed, and kept at -20 ºC for 5 min followed by centrifuging at 15,000 RPM
for 5 min. The supernatant was separated and then centrifuged again. The final supernatant
was analyzed by RP-HPLC 43.
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7.4. Preliminary In Vivo Toxicity Study in Mice.
5-weeks-old male CD-1 mice (purchased from Charles River) were randomly
distributed into 5 groups (n=4) with similar mean body weight. The mice received either
vehicle (1.5% DMSO, 10% Ethanol, 20% PEG 400, and ~70% sterile water), EVCit-TFM (3.1
mg/kg equivalent to 1200 nmol/kg), EVCit-BFM (2.5 mg/kg equivalent to 1200 nmol/kg),
VCit-TFM (3 mg/kg equivalent to 1200 nmol/kg), and MMAE (0.4 mg/kg equivalent to 600
nmol/kg) through intraperitoneal injection (i.p.), every 5 days for a total 4 doses. The body
weight of each mouse was recorded every 3 days for a total of 21 days. The animal’s body
weight changes from the start of treatment were calculated as mean body weight change (±
s.d.) % from day 0 for each group. The mice with body weights falling below 20% from the
start of the treatment were euthanized 43.
7.5. Binding Affinity of EVCit-TFM and VCit-TFM to TTR in Buffer.
The affinity of EVCit-TFM and VCit-TFM to TTR in solution was quantified by their
capacity to displace the FP probe from TTR by already established fluorescence polarization
(FP) assay
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. EVCit-TFM and VCit-TFM were serially diluted (0.010 μM to 20 μM) and

mixed with a solution of FP-probe (50 nM) and TTR (300 nM) in assay buffer (PBS pH 7.4,
0.01% TritonX100, 1% DMSO in 25 μL final volumes) in 384-well plate. The samples were
agitated for 20 min at room temperature to make the solution in equilibrium.

The

fluorescence polarization condition was set as excitation wavelength 485 nm, emission
wavelength 525 nm, and Cutoff wavelength 515 nm. The measurements were taken in
SpectraMax M5Microplate Reader (Molecular Devices).

The IC50 values were obtained by

fitting the data to the following equation [y = (A − D)/ (1 + (x/C)B) + D], where A = maximum
FP signal, B = slope, C = apparent binding constant (Kapp), and D = minimum FP signal. The
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IC50 values were plotted on the Cheng−Prusoff equation to calculate the binding constant (Kd).
All reported data represent the mean ± s.d. (n = 3).
7.6. Binding Affinity and Selectivity of Ligands to TTR in Human and Mouse Serum.
The binding affinity and selectivity of EVCit-TFM and VCit-TFM to TTR in serum
were quantified by their capacity to compete with the binding of fluorescent probe exclusion
(FPE probe) binding to TTR in human serum, as reported earlier 72,73 . AG10 (TTR stabilizer
in phase 3 trial) and Tafamidis (FDA-approved TTR stabilizer) were used as positive controls.
98 μL of human serum was mixed with 1 μL of test compounds (1.0 mM stock solution in
DMSO; 10 μM final concentration in serum) and 1 μL of FPE probe (0.36 mM stock solution
in DMSO; 3.6 μM final concentration in serum) in the 96 clear bottom assay plate. The
fluorescence changes (λex = 328 nm and λem = 384 nm) were monitored every 15 min using
a SpectraMax M5 microplate reader for 6 h at 25 ºC. The assay was also performed using
Mouse Balb C Serum (#IMSBCSER; Innovative Research) following the same protocol
described above for human serum 43.
7.7. In Vitro Analysis of MMAE Release Following Cathepsin B Cleavage.
Cathepsin B, collected from the human liver, was obtained at a concentration of 14.32
μM in 20 mM sodium acetate and 1 mM EDTA at pH 5.0. The enzyme was activated by
incubating for 15 min with 25 mM sodium acetate, 1 mM EDTA, and 9.2 mM DTT at pH 5.5
at ambient temperature. The final concentration of activated cathepsin B (100 nM) was mixed
with MMAE, EVCit-TFM, VCit-TFM, or EVCit-BFM (final concentration of 20 μM) in the
reaction buffer (25 mM sodium acetate and 1 mM EDTA at pH 5.5) at 37 ºC. Aliquots of the
sample were taken at 0, 15 min, 30 min, and 1 h. Each sample aliquot was immediately
quenched by HPLC solvent B mixed by vertexing, placed at -20 ºC for 5 min, centrifuged at
15,000 RPM for 5 min two times, and the supernatant was analyzed by the same HPLC method
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used for the stability assay mentioned above. The identity of the hydrolysis products from
EVCit-TFM, EVCit-BFM, and VCit-TFM was confirmed by HPLC and MS analysis. Similar
experiment was performed for EVCit-TFM using mouse cathepsin B 43.
7.8. Effect of TTR on the Cytotoxicity of EVCit-TFM, EVCit-BFM
Cell viability (MTT) assay was performed using CellTiter 96 Non-Radioactive Cell
Proliferation Assay. Two prostate cancer cell lines, LNCaP (PSMA+) and DU145 (PSMA-)
and HeLa (PSMA-) cells were cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum, penicillin/streptomycin (100 unit/mL and 100µg/mL respectively) and 1% LGlutamine under the humidified atmosphere of 5% CO2 and 95% air at 37 ºC. The cells were
grown to about 75% confluence and seeded into 96-well plates at ~5,000 cells/well density and
then treated with EVCit-TFM, EVCit-BFM, and VCit-TFM (each at 0.001 nM to 100000 nM)
or MMAE (0.001 nM to 1000 nM) as a positive control in the presence and absence of TTR.
The presence of TTR was maintained by applying 1 µM TTR and allowed to incubate for 30
min with test compounds. Control cells were also treated with the appropriate concentration
of vehicle (DMSO) in the absence and presence of TTR. Cell viability was determined
following the standard CellTiter 96 Non-Radioactive Cell Proliferation Assay protocol after 72
h incubation at 37 ºC and 5% CO2 43.
7.9. In Vivo Dose-escalation Study in Mice.
5-weeks-old male athymic nude mice (purchased from Charles River) were randomized
into groups (n=4) with similar mean body weight. The mice received either vehicle (1.5%
DMSO, 10% ethanol, 20% PEG 400, and ~70% sterile water), EVCit-TFM (3.1 mg/kg
equivalent to 1200 nmol/kg and 6.3 mg/kg), EVCit-BFM (2.5 mg/kg equivalent to 1200
nmol/kg, 5 mg/kg, and 10 mg/kg). For docetaxel, the dosing solution was prepared by
dissolving the compound in 5% Tween-80, 5% ethanol, and ~90% (5% dextrose solution). The
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docetaxel doses were 10 mg/kg, 20 mg/kg, and 40 mg/kg. Test compounds were injected via
intraperitoneal (i.p.) injection, every five days for a total of 4 doses. Body weight was recorded
every three days for 21 days.

Body weight changes from the beginning of treatment for the

animals were calculated as mean (± s.d.) % change from day 0 for each group. The mice with
body weights falling below 20% from the start of the treatment were euthanized 43.
7.10. Mouse Xenograft Tumor Model Generation.
LNCaP (PSMA+) (prostate cancer cells) were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum, penicillin/streptomycin (100 unit/mL and 100
µg/mL, respectively), and 1% L-Glutamine under the humidified atmosphere of 5% CO2 and
95% air at 37 ºC. The cells were grown to 75% confluence, detached by trypsinization, and
washed twice with cold HBSS, centrifuged at 125g for 10 min at 4 ºC to collect the cells. The
cells were then resuspended, counted, and the total and percent viable cells was determined
using hemocytometer and trypan blue. A total of 5×106 LNCaP (PSMA+) cells were suspended
in 100 µL of 1:1 (v/v) HBSS: Matrigel (Becton Dickinson) mixture, injected on the right flanks
of male athymic nude mice.

Tumor volumes were measured with a digital caliper every three

days and calculated as V = (L × W2)/2 assuming ellipsoid tumor shape. Whenever the tumor
volume reached 100-150 mm3 within (10-14 days), mice were randomized into groups with
similar mean tumor volume and body weight for in vivo efficacy studies 43.
7.11. In Vivo Efficacy studies using Mouse LNCaP Xenograft Model of Prostate Cancer.
Mice (n=7) bearing LNCaP (PSMA+) tumors received either vehicle or EVCit-TFM,
EVCit-BFM, and docetaxel via i.p. injection every 5 days for a total of 7 doses (over 30 days).
Body weight and tumor volumes were recorded every three days up to 100 days (total duration
of the study). The endpoint is defined as when the tumor size in any animal reaches 2000 mm3
or there was a loss of more than 20% in body weight from the start of the treatment. The mice
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that were euthanized because of reaching the endpoint, their terminal tumor volumes were used
for calculating the mean tumor volume for that group 43.
7.12. Statistical Analysis.
All results are expressed as mean ± s.d. Statistical analysis was performed with
GraphPad PRISM 9 software. Statistical significance for invitro stability assay was done by
one-way ANOVA followed by Tukey’s multiple comparison test. The significance of the
differences in in vivo studies was performed by comparing vehicles to other groups by oneway ANOVA followed by Dunnett multiple comparison test and through Log-rank (MantelCox) test indicated as (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤
0.0001) 43.
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